EDSA (Edesa Biotech) Cyclically Adjusted FCF per Share: $-47.14 (As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.42
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech Cyclically Adjusted FCF per Share?

Edesa Biotech EDSA -3.87% 26 Cyclically Adjusted FCF per Share is $-47.14 as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Edesa Biotech's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.236. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-47.14 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 20.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Edesa Biotech was 20.60% per year. The lowest was 7.30% per year. And the median was 14.30% per year.

As of today (2026-07-07), Edesa Biotech's current stock price is $7.42. Edesa Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-47.14. Edesa Biotech's Cyclically Adjusted Price-to-FCF of today is .


Edesa Biotech  (NAS:EDSA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Edesa Biotech Cyclically Adjusted FCF per Share Related Terms


Edesa Biotech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech Cyclically Adjusted FCF per Share Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -139.10 -115.48 -99.20 -78.20 -57.84

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.70 -62.37 -57.84 -51.61 -47.14

EDSA vs ACET, HRTX, ENTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Edesa Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edesa Biotech Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Cyclically Adjusted Price-to-FCF falls into.


EDSA
26GF Score
Edesa Biotech Inc EDSA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Edesa Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.236/132.2623*132.2623
=-0.236

Current CPI (Mar. 2026) = 132.2623.

Edesa Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -37.862 102.002 -49.094
201609 -38.206 101.765 -49.656
201612 -42.618 101.449 -55.563
201703 -38.765 102.634 -49.956
201706 -28.971 103.029 -37.191
201709 -33.861 103.345 -43.336
201712 -32.750 103.345 -41.914
201803 -43.306 105.004 -54.548
201806 -17.356 105.557 -21.747
201809 -7.811 105.636 -9.780
201812 -10.354 105.399 -12.993
201903 -10.126 106.979 -12.519
201906 -3.622 107.690 -4.448
201909 -1.236 107.611 -1.519
201912 -0.737 107.769 -0.904
202003 -0.937 107.927 -1.148
202006 -1.069 108.401 -1.304
202009 -1.255 108.164 -1.535
202012 -2.052 108.559 -2.500
202103 -4.319 110.298 -5.179
202106 -1.650 111.720 -1.953
202109 -0.186 112.905 -0.218
202112 -1.684 113.774 -1.958
202203 -0.211 117.646 -0.237
202206 -1.371 120.806 -1.501
202209 -2.460 120.648 -2.697
202212 -0.682 120.964 -0.746
202303 -0.551 122.702 -0.594
202306 -0.616 124.203 -0.656
202309 -0.485 125.230 -0.512
202312 -0.450 125.072 -0.476
202403 -0.520 126.258 -0.545
202406 -0.266 127.522 -0.276
202409 -0.298 127.285 -0.310
202412 -0.454 127.364 -0.471
202503 -0.449 129.181 -0.460
202506 -0.242 129.892 -0.246
202509 -0.244 130.287 -0.248
202512 -0.262 130.366 -0.266
202603 -0.236 132.262 -0.236

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-47.14 mean?
Edesa Biotech (EDSA) has a Cyclically Adjusted FCF per Share of $-47.14 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Edesa Biotech and its competitors.
Is Edesa Biotech's Cyclically Adjusted FCF per Share too high?
Edesa Biotech's current Cyclically Adjusted FCF per Share is $-47.14. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Cyclically Adjusted FCF per Share compare to ACET and HRTX?
Edesa Biotech's Cyclically Adjusted FCF per Share of $-47.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Edesa Biotech and its competitors. Edesa Biotech's current Cyclically Adjusted FCF per Share is $-47.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Cyclically Adjusted FCF per Share of $-47.14. The current Cyclically Adjusted FCF per Share is $-47.14. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Cyclically Adjusted FCF per Share is $-47.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price